A single administration of psilocybin, the psychoactive constituent found in psychedelic fungi, demonstrably alleviates nerve pain for a period extending up to a month and amplifies the efficacy of a commonly employed analgesic, according to research conducted at the University of Reading.
Investigations detailed in the journal Communications Biology involved the administration of psilocybin to murine subjects exhibiting nerve damage that induces persistent pain. The findings indicate that the pain-mitigating effects of psilocybin emerged approximately two hours post-injection, with the relief enduring for several weeks. It appears that rather than merely obstructing pain signal transmission, psilocybin functions by reconfiguring the operational dynamics of the brain’s pain processing neural networks. This mechanism likely accounts for the sustained therapeutic impact, even after the compound has been metabolized and eliminated from the organism.
A particularly noteworthy discovery pertained to the synergistic interaction between psilocybin and gabapentin, a medication frequently prescribed for neuropathic discomfort. When administered to mice weeks after a solitary psilocybin dosage, and after the direct analgesic influence of psilocybin had abated, gabapentin elicited a pain-relieving response that persisted for as long as four days. In contrast, gabapentin exhibited considerably diminished effectiveness in mice that had not received prior psilocybin exposure.
It is recognized that between 30% and 50% of individuals afflicted with nerve pain do not achieve satisfactory alleviation with gabapentin monotherapy.
Millions of individuals grapple with nerve pain that current pharmacological interventions fail to manage adequately. Furthermore, the available treatments can precipitate significant adverse effects or foster dependency. The encouraging aspect of this research lies in psilocybin’s capacity to do more than just ablate pain independently. It seems to recalibrate the neural pathways involved in pain perception, thereby substantially enhancing the therapeutic benefits of established interventions. For patients who have exhausted conventional treatment avenues, this could represent a genuinely transformative development.”
Dr. Maria Maiarú, Senior Author, University of Reading
The analgesic properties were observed consistently in both male and female mice, a significant observation given the historical predilection for conducting early pain research predominantly in male animal models. The experimental design adhered to UK Home Office regulations and the 3Rs principles (Replacement, Reduction, and Refinement), utilizing a limited cohort of rodents. Experimental procedures were meticulously designed to minimize organismal distress, and efforts were made to derive multiple data points from individual animals whenever feasible to reduce the overall number of subjects used.
Askey, T., et al. (2026). Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia. Communications Biology. DOI: 10.1038/s42003-026-10065-7. https://www.nature.com/articles/s42003-026-10065-7
